Over the course of a decade, the therapeutic pendulum in treating urinary incontinence in women swung dramatically from needle suspension and anterior urethropexy to collagen injections and back again to suspension procedures with no sound clinical trials driving the move toward either approach.
Cretostimogene grenadenorepvec reaches high complete response rate in NMIBC
May 3rd 2024The novel oncolytic immunotherapy cretostimogene grenadenorepvec induced complete responses in three-fourths of patients with BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ, according to findings from the phase 3 BOND-003 trial.